Recent trials on immunotherapy drugs have demonstrated significant advancements in cancer treatment. Pembrolizumab (Keytruda) extended survival for head and neck cancer patients to five years, compared to 30 months with standard treatments, while reducing recurrence risks. Additionally, lifileucel showed promise for advanced melanoma, with nearly 20% survival at five years. Car T-cell therapy, a transformative approach for solid tumours, showed patients lived 40% longer with advanced gastric cancer compared to standard care, and shrank tumours in 62% of patients suffering from recurrent glioblastoma—a notable breakthrough.
In the trial, patients treated with Car T-cell therapy lived on average about 40% longer than those receiving standard care for advanced gastric cancers.
Experts hailed the recent trial results as a milestone, as previous immunotherapy drugs haven't succeeded in shrinking recurrent glioblastoma tumours until now.
Collection
[
|
...
]